Drug Delivery Systems 2005 - Sept 6-7, 2005 - London

The 2nd Annual Drug Delivery Systems 2005 Conference will provide delegates with an overview of the current market trends, focusing on the novel, emerging and improvements in technology, covering combination products and the chance to discuss the best practice for business development in the drug delivery systems market.
The conference will open with Pfizer and Boehringer -Igelheim giving their perspectives on how to form successful alliances with drug delivery companies. The best practice for business development will then be discussed, covering bottlenecks and speciality pharmaceutical companies. Novel, emerging and improvements in technology will form a majority of the presentations on the first day of the event by companies such as Nobex, 3M Healthcare, Vyteris, Boehringer Ingelheim and Genzyme Pharmaceuticals.
The second day of the conference will open with a section on technology analysis; covering orally disintegrating tablets by Eurand, lipid-based delivery by Centocor, Johnson & Johnson and nanoparticle drug delivery by Elan.
The conference will round off covering combination products-- approaches to speed the time to market and a case study by GSK on consumer driven drug delivery: how to increase patient compliance. Attend this event to hear from experts in the drug delivery industry on their experience and new concepts.
Key themes to be covered at the 2nd Annual Drug Delivery Systems 2005 Conference:
* How to form successful alliances- perspectives from Pfizer and Boehringer Ingelheim
* Best practice for business development: covering bottlenecks and speciality pharmaceutical companies
* Novel, emerging and improvements in technology- intranasal peptide, respiratory and insulin delivery addressed
* Technology analysis: orally disintegrating tablets (Eurand), lipid-based (Centocor, Johnson & Johnson) and nanoparticle drug delivery (Elan)
* Combination products- approaches to speed the time to market
Key Speakers:
Dr. Karoline Bechtold-Peters, Head of Pharmaceutical Processes, Boehringer Ingelheim
Dr. James Eshelby, Strategic Alliances, Pfizer
Dr. Honghui Zhou, Director, Clinical Pharmacokinetics, Head, Late Stage Pharmacokinetics
Clinical Pharmacology & Experimental Medicine, Centocor, Johnson & Johnson
David Phillips, Technical Licensing, GSK
Dr. Robert Clayborough, Group Leader, 3M Drug Delivery Systems, 3M Healthcare
Florian Witte, Head of Laboratories, Drug Delivery Department, Boehringer Ingelheim GmbH
Dr. Alen Guy, Associate Director Business Development, Eurand
Dr. Christian Wertz, Scientist II, Pharmaceutical Research, Elan NanoSystems
Christopher Price, CEO, Nobex
Dr. Perry Genova, Vice President of Biomedical Engineering, Kos Pharmaceuticals
Kevin Skinner, Associate Director of Science, Biomaterial and Surgical Products, Genzyme